Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 309-312

  Rayner, Christopher K ^a   Jones, Karen L ^a   Wu, Tongzhi ^a   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; OUTCOME ASSESSMENT; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; ADULT; AGONISTS; AUTONOMIC NEUROPATHY; CASE CONTROL STUDY; COMPLICATION; DIABETIC NEUROPATHY; DRUG EFFECT; EMOTION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STOMACH EMPTYING;

ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EMOTIONS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PREVALENCE;

EID: 85006823246     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12822     Document Type: Editorial

References (42)

1. Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther. 2011;33(6):634-649.
2. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36(5):1396-1405.
3. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
4. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
6. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1469-1480; e1461.
7. Crowell MD, Umar SB, Lacy BE, Jones MP, DiBaise JK, Talley NJ. Multi-dimensional gastrointestinal symptom severity index: validation of a brief GI symptom assessment tool. Dig Dis Sci. 2015;60(8):2270-2279.
8. Ghorbani S, Nejad A, Law D, Chua KS, Amichai MM, Pimentel M. Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. Ann Gastroenterol. 2015;28(1):87-93.
9. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20(suppl 7):31-39.
10. Quan C, Talley NJ, Jones MP, Spies J, Horowitz M. Gain and loss of gastrointestinal symptoms in diabetes mellitus: associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up. Am J Gastroenterol. 2008;103(8):2023-2030.
11. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378-384.
12. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996.
13. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97(3):604-611.
14. Eslick GD, Talley NJ. Prevalence and relationship between gastrointestinal symptoms among individuals of different body mass index: a population-based study. Obes Res Clin Pract. 2016;10(2):143-150.
15. Bharucha AE, Batey-Schaefer B, Cleary PA, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology. 2015;149(2):330-339.
16. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med. 1991;18(4):229-234.
17. Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil. 2008;20(6):635-642.
18. Rayner CK, Verhagen MA, Hebbard GS, DiMatteo AC, Doran SM, Horowitz M. Proximal gastric compliance and perception of distension in type 1 diabetes mellitus: effects of hyperglycemia. Am J Gastroenterol. 2000;95:1175-1183.
19. Hebbard GS, Samsom M, Sun WM, Dent J, Horowitz M. Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion. Am J Physiol. 1996;271(5, pt 1):G814-G819.
20. Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. The blood glucose concentration influences postprandial fullness in insulin dependent diabetes mellitus. Diabetes Care. 1997;20:1141-1146.
21. Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15(1):137-142.
22. Toeller M. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest. 1994;24(suppl 3):31-35.
23. Spiller R, Camilleri M, Longstreth GF. Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? Clin Gastroenterol Hepatol. 2010;8(2):125-129; discussion 129–136.
24. Molinder H, Agreus L, Kjellstrom L, et al. How individuals with the irritable bowel syndrome describe their own symptoms before formal diagnosis. Ups J Med Sci. 2015;120(4):276-279.
25. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737-1749.
26. Talley NJ, Phillips SF, Melton J III, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med. 1989;111(8):671-674.
27. Quan C, Talley NJ, Cross S, et al. Development and validation of the diabetes bowel symptom questionnaire. Aliment Pharmacol Ther. 2003;17(9):1179-1187.
28. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35-42.
29. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785-790.
30. Drucker DJ, Buse JB, Taylor K, et al., DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
31. Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263-1273.
32. Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(1):G120-G128.
33. Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65(1):269-275.
34. Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1-3):77-83.
35. Jones KL, Horowitz M, Wishart JM, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med. 1995;36:2220-2228.
36. Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):954-965.
37. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med. 2013;6:877-895.
38. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
39. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3):313-318.
40. Baraboi ED, St-Pierre DH, Shooner J, Timofeeva E, Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1011-R1024.
41. Bettge K, Kahle M, Abd El Aziz M, Meier JJ, Nauck M. Occurrence of nausea, vomiting, and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a meta-analysis. Diabetes Obes Metab. 2016. doi: 10.1111/dom.12824
42. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317-332.